

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED COUNSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

VOLUNTARY ANNOUNCEMENT DISPOSAL OF THE TARGET GROUP

This announcement is made by Tigermed Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that on October 10, 2025, the Company, Jiaxing Xinge Medical Consulting Co., Ltd.* (嘉興欣格醫藥科技有限公司), a wholly-owned subsidiary of the Company (together with the Company, the “**Vendors**”), and Frontage Laboratories (Shanghai) Co., Ltd.* (方達醫藥技術(上海)有限公司) (the “**Purchaser**”), a wholly-owned subsidiary of Frontage Holdings Corporation (“**Frontage Holdings**”, together with its subsidiaries, the “**Frontage Group**”) entered into a share transfer agreement (the “**Share Transfer Agreement**”), pursuant to which the Purchaser has conditionally agreed to acquire, and the Vendors have conditionally agreed to sell the entire issued share capital of Teddy Clinical Research Laboratory (Shanghai) Ltd.* (上海觀合醫藥科技股份有限公司) (the “**Target Company**”), at the total consideration of RMB270,000,000 (the “**Disposal**”).

As of the date of this announcement, Frontage Holdings is a subsidiary of the Company, whose shares are listed on The Stock Exchange of Hong Kong Limited (stock code: 3347). Therefore, upon completion of the Disposal, the Target Company, as well as Teddy Clinical Research Laboratory (Hong Kong) Limited and Teddy Clinical Research Laboratory (Wuxi) Ltd.* (無錫觀合醫學檢驗所有限公司) (each a subsidiary of the Target Company, together with the Target Company, the “**Target Group**”) will remain as subsidiaries of the Company.

The total consideration for the Disposal was determined after arm's length negotiations among the parties to the Share Transfer Agreement with reference to the valuation of the entire equity interest of the Target Company of RMB270,000,000 as of June 30, 2025 (taking into account the effect of the completion of the repurchase and capital reduction of the Target Company) as appraised by Asia-Pacific Consulting and Appraisal Limited based on the market approach.

The completion of the Disposal is contingent upon the fulfillment of the conditions precedent outlined in the Share Transfer Agreement, including the requirement for Frontage Holding to obtain independent shareholders' approval at a general meeting. For further information, please refer to the announcement dated October 10, 2025 published by Frontage Holdings in relation to the Disposal.

As the Disposal is an intra-group transaction, it is expected that the Disposal would not have any material impact on the consolidated statement of the financial position of the Group.

The Company is a leading China-based provider of comprehensive biopharmaceutical research and development services, with an expanding global presence and is principally engaged in the provision of one-stop and professional clinical research services for innovative drugs, medical devices and biotechnology related products to domestic and international enterprises engaged in providing innovative drugs and medical devices. The Target Group is principally engaged in clinical trial services. The Frontage Group is engaged in the provision of research, analytical and development services throughout the product discovery and development continuum.

The Board is of the view that the Disposal allows the Group to optimize its resource allocation and enhance operational efficiency through the integration of internal resources. As the Frontage Group are also subsidiaries of the Group, the Disposal facilitates better alignment of business functions and promotes synergies within the Group's overall structure. By consolidating the Target Group's operations under the Frontage Group, the Group can centralize management and streamline decision-making process, thereby improving cost efficiency and operational focus.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, October 10, 2025

As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Mr. Wen Zengyu; the independent non-executive Directors are Mr. Liu Kai Yu Kenneth, Mr. Yuan Huagang and Ms. Liu Yuwen.

* For identification purposes only